Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alendronic acid

Drug Profile

Alendronic acid

Alternative Names: Adronat; AHButBP; Alend; Alendronate; Alendronate disodium; Alendronate sodium hydrate; Alendros; Bonalon; Bonalon Jelly; Dronal; Fosalan; Fosamax; G 704650; GTH 42; GTH-42J; GTH-42V; GTH-42W; L 670452; Marvil; MK 217; Onclast; Osteosan®; Sodium alendronate trihydrate; Teiroc

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gador; Istituto Gentili
  • Developer Teijin Pharma
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Corticosteroid-induced osteoporosis; Fracture; Male osteoporosis; Malignant hypercalcaemia; Osteitis deformans; Osteoporosis; Postmenopausal osteoporosis
  • No development reported Bone resorption

Most Recent Events

  • 15 May 2023 Generic equivalent approved in USA
  • 05 Feb 2014 MSD Korea and Hanmi Pharmaceutical agree to co-promote alendronic acid in South Korea for prevention of osteoporosis
  • 15 Aug 2012 Registered for Osteoporosis in Japan (PO, Jelly, 35mg, once-weekly)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top